Col, Omer Faruk et al. published their research in Journal of Molecular Structure in 2022 | CAS: 2166-13-4

6-(4-Chlorophenyl)pyridazin-3(2H)-one (cas: 2166-13-4) belongs to pyridazine derivatives. The pyridazine structure is also found within the structure of several drugs such as cefozopran, cadralazine, minaprine, pipofezine, and hydralazine. Pyridazine is bioavailable (especially in the CNS) and can reduce toxicity. Pyridazine is a component of several drug molecules, and the pyridazine pharmacophore has contributed to a variety of pharmacologically active compounds.Related Products of 2166-13-4

3(2H)-Pyridazinone derivatives: Synthesis, in-silico studies, structure-activity relationship and in-vitro evaluation for acetylcholinesterase enzyme inhibition was written by Col, Omer Faruk;Bozbey, Irem;Turkmenoglu, Burcin;Uysal, Mehtap. And the article was included in Journal of Molecular Structure in 2022.Related Products of 2166-13-4 This article mentions the following:

New ten compounds bearing pyridazinone ring I [R = Me, MeO, Cl; R1 = H, F3C, F, Cl] were designed and synthesized as acetylcholinesterase inhibitors. The new derivatives I were acquired via the reaction of propionohydrazides with substituted/nonsubstituted sulfonylchlorides. The structures of the synthesized compounds I were explained using FT-IR, 1H-NMR, 13C-NMR, elemental anal. and HRMS spectra. The inhibition profiles of the synthesized compounds I on AChE were researched by comparing their IC50 and KI values. According to the activity studies, all the compounds I showed significant inhibitory activity against AChE relative to the reference compound Tacrine. The compound I [R = Me, R1 = F] showed the best acetylcholinesterase inhibitory effect with a KI value of 11.61 ± 0.77 nM. For all compounds, I the parameters of the interaction points on the receptor side were determined on the ligand basis with the 4D-QSAR model. The synthesized pyridazinone derivatives, I were screened for their acetylcholinesterase inhibitory potential, and the results determined that among the series, compounds I [R = Me, R1 = F, Cl; R = MeO, R1 = F3C] showed the best inhibition, resp. For anti-Alzheimer activities, compounds I [R = Me, R1 = F, Cl; R = MeO, R1 = F3C] were performed in-silico studies to understand the binding site, binding energy properties in mol. docking. In the experiment, the researchers used many compounds, for example, 6-(4-Chlorophenyl)pyridazin-3(2H)-one (cas: 2166-13-4Related Products of 2166-13-4).

6-(4-Chlorophenyl)pyridazin-3(2H)-one (cas: 2166-13-4) belongs to pyridazine derivatives. The pyridazine structure is also found within the structure of several drugs such as cefozopran, cadralazine, minaprine, pipofezine, and hydralazine. Pyridazine is bioavailable (especially in the CNS) and can reduce toxicity. Pyridazine is a component of several drug molecules, and the pyridazine pharmacophore has contributed to a variety of pharmacologically active compounds.Related Products of 2166-13-4

Referemce:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem